$NUMD
Nu-Med Plus, Inc.

2024 Q3 Form 10-Q Financial Statement

#000154812324000107 Filed on August 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.04K $23.07K
YoY Change -30.47% -60.12%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $17.42K $16.04K $23.07K
YoY Change 14.99% -30.48% -60.27%
Operating Profit -$17.42K -$16.04K -$23.07K
YoY Change 14.99% -30.48% -60.27%
Interest Expense -$1.250K $1.247K
YoY Change -200.24%
% of Operating Profit
Other Income/Expense, Net -$1.260K -$1.247K -$1.247K
YoY Change 0.0% 0.0%
Pretax Income -$18.68K -$17.29K -$24.32K
YoY Change 13.84% -28.92% -58.12%
Income Tax
% Of Pretax Income
Net Earnings -$18.68K -$17.29K -$24.32K
YoY Change 13.84% -28.92% -58.12%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 83.55M shares 83.55M shares 81.35M shares
Diluted Shares Outstanding 81.35M shares 81.35M shares 81.35M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.040K $29.96K
YoY Change -86.52%
Cash & Equivalents $4.041K $4.041K $29.96K
Short-Term Investments
Other Short-Term Assets $7.000K $6.590K
YoY Change 6.22% 3.78%
Inventory
Prepaid Expenses $2.800K $7.000K $6.590K
Receivables
Other Receivables $0.00
Total Short-Term Assets $6.841K $11.04K $36.55K
YoY Change -50.24% -69.79% 475.54%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $6.841K $11.04K $36.55K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $6.841K $11.04K $36.55K
YoY Change -50.24% -69.79% 333.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.85K $9.225K $14.24K
YoY Change 201.44% -35.21% -76.09%
Accrued Expenses $17.05K $19.09K $3.479K
YoY Change 259.77% 448.84% -97.41%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $100.0K
YoY Change 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $211.4K $196.9K $152.1K
YoY Change 45.08% 29.46% -40.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $211.4K $196.9K $152.1K
Total Long-Term Liabilities $0.00
Total Liabilities $211.4K $196.9K $152.1K
YoY Change 45.08% 29.46% -40.48%
SHAREHOLDERS EQUITY
Retained Earnings -$9.883M -$9.864M -$9.752M
YoY Change 1.17% 1.15% 0.7%
Common Stock $83.55K $83.55K $81.35K
YoY Change 2.7% 2.7% 2.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$204.5K -$185.9K -$115.5K
YoY Change
Total Liabilities & Shareholders Equity $6.841K $11.04K $36.55K
YoY Change -50.24% -69.79% 333.02%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$18.68K -$17.29K -$24.32K
YoY Change 13.84% -28.92% -58.12%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$2.320K -$23.07K
YoY Change -89.94% 808.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.320K -23.07K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000
Net Change In Cash -2.320K -23.07K
YoY Change -89.94% 808.27%
FREE CASH FLOW
Cash From Operating Activities -$2.320K -$23.07K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q2 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
us-gaap Revenues
Revenues
usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81348469 shares
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-54808
dei Entity Registrant Name
EntityRegistrantName
NU-MED PLUS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-3672530
dei Entity Address Address Line1
EntityAddressAddressLine1
640 Belle Terre Rd. 2 E
dei Entity Address City Or Town
EntityAddressCityOrTown
Port Jefferson
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11777
dei City Area Code
CityAreaCode
(631)
dei Local Phone Number
LocalPhoneNumber
403-4337
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83548469 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4041 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6806 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6650 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
11041 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13456 usd
CY2024Q2 us-gaap Assets
Assets
11041 usd
CY2023Q4 us-gaap Assets
Assets
13456 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9225 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8089 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
100000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
100000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19094 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
196905 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
160207 usd
CY2024Q2 us-gaap Liabilities
Liabilities
196905 usd
CY2023Q4 us-gaap Liabilities
Liabilities
160207 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83548469 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83548469 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83548469 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83548469 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
83549 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
83549 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9594687 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9594687 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9864100 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9824987 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-185864 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-146751 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11041 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13456 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12835 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6573 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18819 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12990 usd
CY2023Q2 numd Operating Rent Expense
OperatingRentExpense
3300 usd
numd Operating Rent Expense
OperatingRentExpense
300 usd
numd Operating Rent Expense
OperatingRentExpense
6600 usd
CY2024Q2 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
3205 usd
CY2023Q2 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
13200 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
17500 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
30455 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
16040 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
23073 usd
us-gaap Operating Expenses
OperatingExpenses
36619 usd
us-gaap Operating Expenses
OperatingExpenses
50045 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16040 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23073 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-36619 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-50045 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1247 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1247 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2493 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2479 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1247 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1247 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2493 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2479 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17287 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24320 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39112 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52524 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-17287 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24320 usd
us-gaap Net Income Loss
NetIncomeLoss
-39112 usd
us-gaap Net Income Loss
NetIncomeLoss
-52524 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81348469 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81348469 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81348469 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81348469 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-146751 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-21826 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-168577 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-17287 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-185864 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63025 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-91229 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24320 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-115549 usd
us-gaap Net Income Loss
NetIncomeLoss
-39112 usd
us-gaap Net Income Loss
NetIncomeLoss
-52524 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
350 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
240 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2178 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7047 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
21426 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13093 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2479 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2765 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43238 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2765 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43238 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6806 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73195 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4041 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29957 usd
CY2024Q2 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
20 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">c. Estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</p>
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
500 usd
us-gaap Weighted Average Numer Diluted Limited Partnership Units Outstanding Adjustment
WeightedAverageNumerDilutedLimitedPartnershipUnitsOutstandingAdjustment
0 shares
us-gaap Weighted Average Numer Diluted Limited Partnership Units Outstanding Adjustment
WeightedAverageNumerDilutedLimitedPartnershipUnitsOutstandingAdjustment
0 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">h. Concentrations and Credit Risk <b><i>- </i></b>The Company has relied on a small group of investors to fund its operations. If this group becomes unable or unwilling to provide additional funding, the Company may be unable to remain in business or to execute on its business plan.</p>
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1200000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
83893 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
90368 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
83893 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
90368 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83548469 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83548469 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83548469 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83548469 shares
numd Monthly Office Rent Expenses
MonthlyOfficeRentExpenses
100 usd
numd Reimbursement Of Office Expenses
ReimbursementOfOfficeExpenses
500 usd
numd Reimbursement Of Office Expenses
ReimbursementOfOfficeExpenses
0 usd
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
usd
CY2024Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
usd
CY2023Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
usd
CY2024Q2 numd Operating Rent Expense
OperatingRentExpense
usd
CY2024Q2 us-gaap Depreciation
Depreciation
usd
CY2023Q2 us-gaap Depreciation
Depreciation
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Depreciation
Depreciation
usd
CY2024Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
CY2023Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81348469 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81348469 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81348469 shares
us-gaap Depreciation
Depreciation
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Depreciation
Depreciation
usd
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001543637

Files In Submission

Name View Source Status
0001548123-24-000107-index-headers.html Edgar Link pending
0001548123-24-000107-index.html Edgar Link pending
0001548123-24-000107.txt Edgar Link pending
0001548123-24-000107-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
numd-20240630.htm.htm Edgar Link pending
numd-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
numd-20240630_cal.xml Edgar Link unprocessable
numd-20240630_def.xml Edgar Link unprocessable
numd-20240630_lab.xml Edgar Link unprocessable
numd-20240630_pre.xml Edgar Link unprocessable
numd-20240630.htm_htm.xml Edgar Link completed